Loading...
•
Mar 31, 2021
Sana Q1 2021 Earnings Report
Sana Biotechnology reported financial results and business highlights for the first quarter of 2021.
Key Takeaways
Sana Biotechnology reported a net loss of $180.6 million, or $1.52 per share, for the three months ended March 31, 2021. The company's cash, cash equivalents, and marketable securities totaled $981.9 million as of March 31, 2021.
Presented key proof of concept data for multiple platforms at AACR 2021.
Cash position was $981.9 million as of Q1 2021.
Completed initial public offering in February 2021, issuing 27.0 million shares at $25.00 per share.
Research and development expenses for the three months ended March 31, 2021 were $168.9 million.
Forward Guidance
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical development plans and timing expectations; updates at scientific and medical conferences; and the ability to make CAR T cells that evade the innate and adaptive immune system or that persist without immunosuppression.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...